SMALL LYMPHOCYTIC LYMPHOMA

This large, late-stage study is comparing two drug combinations for younger patients with untreated chronic lymphocytic leukemia (CLL). It tests whether adding a third drug, venetoclax, to the standard two-drug combination of ibrutinib and obinutuzumab leads to better disease con…

This study is testing whether combining two cancer drugs, tafasitamab and zanubrutinib, is safe and effective for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if using both drugs together can kill more canc…

This study is testing a combination of four drugs as the first treatment for patients with a specific genetic type of chronic lymphocytic leukemia (CLL). The goal is to see if using these drugs together—a targeted therapy, two chemotherapy drugs, and an immunotherapy—is more effe…

This study is for adults 65 and older with untreated chronic lymphocytic leukemia (CLL), a type of blood cancer. It compares the standard two-drug treatment (ibrutinib + obinutuzumab) against an experimental three-drug combination that adds a medication called venetoclax. The mai…

This study is testing whether adding a new drug called pirtobrutinib to a standard two-drug combination works better for people with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 600 participants will be randomly assigned to receive either t…

This study is testing a two-drug combination (pirtobrutinib and venetoclax) for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The main goal is to see if using a sensitive blood test that detects tiny amounts of leftover c…

This study is testing whether starting a cancer drug called ibrutinib early, before symptoms appear, can better control high-risk forms of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It involves 42 patients who have these cancers with specific high-ri…

This study is testing whether a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—can control the growth of chronic lymphocytic leukemia (CLL). It is enrolling adults with CLL, including those whose cancer has come back after treatment and those who have never…

This study is testing a new drug called epcoritamab to see if it is safe and effective for people with certain hard-to-treat blood cancers. It is for adults with chronic lymphocytic leukemia (CLL) or Richter's syndrome that has come back or not responded to other treatments. The …

This study is testing if giving a low-dose cancer drug (lenalidomide) along with a standard pneumonia vaccine can help the body's immune system better recognize and attack early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It enrolled 49 adults wi…

This study is testing whether giving vitamin D supplements to cancer patients who have low vitamin D levels can help improve their survival and delay the need for other treatments. It focuses on people newly diagnosed with certain aggressive lymphomas or a slow-growing type of le…

This is a first-in-human safety study testing a new, experimental CAR-T cell therapy called CAR19.20.22 in adults with B-cell lymphomas that have returned or not responded to at least two prior treatments. The therapy uses the patient's own immune cells, engineered to attack canc…

This study tests whether taking two oral medications together—venetoclax and ibrutinib—can better control chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is for adults whose cancer has returned after prior treatment or who have high-risk, untreated dis…

This study is testing an experimental drug called iopofosine I 131 in people with various advanced B-cell blood cancers that have come back or stopped responding to standard treatments. The drug is designed to deliver radiation directly to cancer cells. The main goal is to see if…

This is a very early-stage study to test the safety and find the right dose of a new oral drug called ABBV-453 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or stopped responding to at least two prior treatments. Particip…

This study is testing a faster, daily schedule for increasing the dose of the drug venetoclax in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if this accelerated 5-day schedule is as safe as the standard 5-week schedule,…

This study is testing a new type of personalized immune cell therapy called rapcabtagene autoleucel (a CAR-T cell therapy) for adults with several aggressive or returning blood cancers. The main goals are to find a safe and effective dose and to see if the therapy can shrink or e…

This study tested a new oral medication called acalabrutinib for adults with chronic lymphocytic leukemia (CLL) and related cancers that have come back or stopped responding to other treatments. The main goals were to find a safe dose and see if the drug could shrink the cancer. …

This study is testing whether a new oral medication called pirtobrutinib works better than standard chemotherapy for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 309 participants will be randomly assigned to receive eit…

This study is testing a new oral medication called nemtabrutinib for people with advanced B-cell blood cancers that have come back or stopped responding to other treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It is for a…

This trial is testing a drug called epcoritamab, alone or combined with standard treatments, for Japanese adults with B-cell lymphomas that have returned or not responded to prior therapy. The first part finds the safest and most effective dose. The second part treats more people…

This study is testing whether combining three different drugs works better for people with chronic lymphocytic leukemia (CLL) or a more aggressive form called Richter transformation that has returned or hasn't responded to other treatments. The combination includes two immunother…

This study is testing a two-drug combination for people with certain slow-growing types of B-cell lymphoma who have not yet received treatment. The goal is to see how well the pill ixazomib works when given with the antibody drug rituximab to shrink tumors and control the cancer.…

This study is testing whether a new oral medication called nemtabrutinib works better than standard chemoimmunotherapy for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), which are types of blood cancer. The main goal is to…

This large study is comparing two different treatment approaches for younger patients with a common type of blood cancer called chronic lymphocytic leukemia (CLL). One group receives a newer, targeted pill (ibrutinib) plus an antibody drug. The other group gets the standard, more…

This large, international study is testing whether a new oral drug called zanubrutinib works better than the standard combination of bendamustine and rituximab chemotherapy for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The…

This study is testing an experimental drug called BGB-11417 in adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned or stopped responding to standard treatments. The trial aims to see how well the drug controls the cancer and how safe it is for pat…